Search Browse Earnings

Neuphoria Therapeutics Inc. — SlamSEC

Neuphoria Therapeutics Inc.

Nasdaq:NEUP

Pharmaceutical Preparations·BURLINGTON, MA

Overview All Filings Sum Fin Credit Insiders Governance

Overview All Filings Sum Fin Credit Insiders Governance

Summary Financials

Revenue

$15.6M

FY 2025

Adj. EBITDA

-$17.2M

-110.1% margin

FY 2025

Net Income

-$15.5M

-99.0% margin

FY 2025

EPS (Diluted)

-$18.62

FY 2025

Stock Price

$4.51

-0.7%

2026-03-09

52W Range

$3.65 – $21.40

P/E Ratio

-0.2x

Market Cap

$24.3M

Cash

$12.6M

FY 2025

Total Debt

—

Net Cash

$12.6M

FY 2025

Enterprise Value

$11.7M

Debt / EBITDA

0.7x

FY 2025

EV / EBITDA

-0.7x

Employees

—

CEO

Papapetropoulos Spyros